ABSTRACT
SUMMARY BACKGROUND: Cerebrovascular accident (or stroke) and ischemic heart disease are the the major causes of death in the world. It is estimated that about 85% of strokes are ischemic in origin. Reperfusion therapy in the acute phase of ischemic stroke with a recombinant human tissue plasminogen activator is effective, but some factors influence the success of this treatment. OBJECTIVE: The aim of this study was to evaluate clinical aspects and possible determinants for reperfusion after venous thrombolysis. METHODS: This is a retrospective, cross-sectional, observational study based on a review of hospital records of inpatients diagnosed with ischemic stroke treated with intravenous thrombolysis, the main outcome being reperfusion or not. RESULTS: Data from this study revealed a predominance of females in the group of reperfused patients and males in the non-reperfused group, both maintaining moderate severity on the National Institutes of Health Stroke Scale and admission without statistical significance (p>0.18). In addition, the mean admission severity score was 13.2 for the group of reperfused patients and 14.2 for those not reperfused, and the mean ejection fraction of both groups was within normal functionality, with a mean of 0.50 for reperfused patients and 0.62 for non-reperfused patients. CONCLUSION: We found an association between successful venous chemical thrombolysis reperfusion and lower mortality in patients with acute stroke.
ABSTRACT
BACKGROUND: Cerebrovascular accident (or stroke) and ischemic heart disease are the the major causes of death in the world. It is estimated that about 85% of strokes are ischemic in origin. Reperfusion therapy in the acute phase of ischemic stroke with a recombinant human tissue plasminogen activator is effective, but some factors influence the success of this treatment. OBJECTIVE: The aim of this study was to evaluate clinical aspects and possible determinants for reperfusion after venous thrombolysis. METHODS: This is a retrospective, cross-sectional, observational study based on a review of hospital records of inpatients diagnosed with ischemic stroke treated with intravenous thrombolysis, the main outcome being reperfusion or not. RESULTS: Data from this study revealed a predominance of females in the group of reperfused patients and males in the non-reperfused group, both maintaining moderate severity on the National Institutes of Health Stroke Scale and admission without statistical significance (p>0.18). In addition, the mean admission severity score was 13.2 for the group of reperfused patients and 14.2 for those not reperfused, and the mean ejection fraction of both groups was within normal functionality, with a mean of 0.50 for reperfused patients and 0.62 for non-reperfused patients. CONCLUSION: We found an association between successful venous chemical thrombolysis reperfusion and lower mortality in patients with acute stroke.
Subject(s)
Brain Ischemia , Ischemic Stroke , Stroke , Female , Humans , Male , Brain Ischemia/complications , Cross-Sectional Studies , Ischemic Stroke/complications , Ischemic Stroke/drug therapy , Observational Studies as Topic , Reperfusion , Retrospective Studies , Stroke/drug therapy , Tissue Plasminogen Activator/therapeutic use , Treatment OutcomeABSTRACT
OBJECTIVE: To verify the association between sociodemographic, clinical, environmental, cognitive, and emotional factors and the decision time of people with ischemic stroke to seek a health service after the onset of symptoms or wake up stroke. METHOD: Cross-sectional study carried out from March to October 2019, with 304 patients, in a public hospital, a reference in neurology. Data obtained through interview and from medical records. Decision time was analyzed as a geometric mean. In the bivariate and multivariate analyses, linear regression was used and the Akaike Information Criterion was used to select the best model. Statistical significance of 5% was adopted. RESULTS: The geometric mean of decision time was 0.30h (95% CI 0.23-0.39). The final model explained this time in 41%, showing an increase of 0.5 min for people with arterial hypertension; 10.8 min for those who waited for symptoms to improve; 1.4 min for those who were alone at the onset of symptoms; 3.9 min for those at home; 3.2 min for the ones at work; and 2.1 for those on the street/public space. CONCLUSION: The mean decision time for seeking a health service was high and influenced by clinical, environmental, cognitive, and emotional variables. The results guide nurses regarding health education.
Subject(s)
Ischemic Stroke , Humans , Cross-Sectional Studies , Emotions , Health Education , Hospitals, PublicABSTRACT
OBJECTIVE: To analyze the association between time of arrival at a reference hospital and mortality of people with ischemic stroke. METHOD: Descriptive and inferential statistics were used. Modifying and confounding variables between time of arrival and mortality were observed in the multivariate analysis. The Akaike Information Criterion was used to choose the model. Statistical significance of 5% and risk correction using the Poisson Model were adopted. RESULTS: Most participants arrived within 4.5 hours of symptom onset or wake up stroke to the referral hospital and 19.4% died. The score of the National Institute of Health Stroke Scale was a modifier. In the multivariate model stratified by scale score ≥14, arrival time >4.5h was associated with lower mortality; and age ≥60 years and having Atrial Fibrillation, to higher mortality. In the model stratified by score ≤13, previous Rankin ≥3, and presence of atrial fibrillation were predictors of mortality. CONCLUSION: The relationship between time of arrival and mortality up to 90 days was modified by the National Institute of Health Stroke Scale. Prior Rankin ≥3, atrial fibrillation, time to arrival ≤4.5h, and age ≥60 years contributed to higher mortality.
Subject(s)
Atrial Fibrillation , Ischemic Stroke , Stroke , Humans , Middle Aged , Ischemic Stroke/complications , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Time Factors , Hospitals , Risk FactorsABSTRACT
ABSTRACT Objective: To verify the association between sociodemographic, clinical, environmental, cognitive, and emotional factors and the decision time of people with ischemic stroke to seek a health service after the onset of symptoms or wake up stroke. Method: Cross-sectional study carried out from March to October 2019, with 304 patients, in a public hospital, a reference in neurology. Data obtained through interview and from medical records. Decision time was analyzed as a geometric mean. In the bivariate and multivariate analyses, linear regression was used and the Akaike Information Criterion was used to select the best model. Statistical significance of 5% was adopted. Results: The geometric mean of decision time was 0.30h (95% CI 0.23-0.39). The final model explained this time in 41%, showing an increase of 0.5 min for people with arterial hypertension; 10.8 min for those who waited for symptoms to improve; 1.4 min for those who were alone at the onset of symptoms; 3.9 min for those at home; 3.2 min for the ones at work; and 2.1 for those on the street/public space. Conclusion: The mean decision time for seeking a health service was high and influenced by clinical, environmental, cognitive, and emotional variables. The results guide nurses regarding health education.
RESUMEN Objetivo: Verificar la asociación entre factores sociodemográficos, clínicos, ambientales, cognitivos, y emocionales y el tiempo de decisión de las personas con accidente cerebrovascular isquémico para buscar un servicio de salud luego del inicio de los síntomas o Wake up stroke Método: Estudio transversal realizado de marzo a octubre de 2019, con 304 pacientes, en un hospital público, referencia en neurología. Datos obtenidos por entrevista y de la historia clínica. El tiempo de decisión se analizó como una media geométrica. En los análisis bivariados y multivariados se utilizó la regresión lineal y el Criterio de Información de Akaike para seleccionar el mejor modelo. Se adoptó una significancia estadística del 5% Resultados: La media geométrica del tiempo de decisión fue de 0,30h (IC 95% 0,23-0,39). El modelo final explicó este tiempo en un 41%, mostrando un aumento de 0,5 min para las personas con hipertensión arterial, 10,8 min para las que esperaron a que los síntomas mejoraran, 1,4 min para las que estaban solas al inicio de los síntomas, 3, 9 min para las que estaban en casa, 3,2 min para los que estaban en el trabajo y 2,1 en la calle/vía pública Conclusión: El tiempo promedio de decisión para buscar un servicio de salud fue alto e influenciado por variables clínicas, ambientales, cognitivas y emocionales. Los resultados orientan a los enfermeros hacia la educación en salud.
RESUMO Objetivo: Verificar a associação entre fatores sociodemográficos, clínicos, ambientais, cognitivos e emocionais e o tempo de decisão de pessoas com acidente vascular cerebral isquêmico para procurar um serviço de saúde após o início dos sintomas ou Wake up stroke Método: Estudo transversal realizado de março a outubro de 2019, com 304 pacientes, em hospital público, referência em neurologia. Dados obtidos por entrevista e no prontuário. O tempo de decisão foi analisado em média geométrica. Nas análises bivariadas e multivariada foi usada a regressão linear e o Critério de Informação de Akaike foi usado na seleção do melhor modelo. Adotou- se significância estatística de 5% Resultados: A média geométrica do tempo de decisão foi de 0,30h (IC 95% 0,23-0,39). O modelo final explicou em 41% esse tempo, mostrando aumento de 0,5 min para pessoas com hipertensão arterial; 10,8 min para quem esperou os sintomas melhorarem; 1,4 min para quem estava sozinho no início dos sintomas; 3,9 min para quem estava em casa; 3,2 min no trabalho e 2,1 na rua/via pública Conclusão: A média do tempo de decisão para procura de serviço de saúde foi alta e influenciada por variáveis clínicas, ambientais, cognitivas e emocionais. Os resultados orientam enfermeiros para a educação em saúde.
Subject(s)
Nursing , Stroke , Emergency Medical Services , Therapeutics , Health , Health EducationABSTRACT
ABSTRACT Objective: To analyze the association between time of arrival at a reference hospital and mortality of people with ischemic stroke. Method: Descriptive and inferential statistics were used. Modifying and confounding variables between time of arrival and mortality were observed in the multivariate analysis. The Akaike Information Criterion was used to choose the model. Statistical significance of 5% and risk correction using the Poisson Model were adopted. Results: Most participants arrived within 4.5 hours of symptom onset or wake up stroke to the referral hospital and 19.4% died. The score of the National Institute of Health Stroke Scale was a modifier. In the multivariate model stratified by scale score ≥14, arrival time >4.5h was associated with lower mortality; and age ≥60 years and having Atrial Fibrillation, to higher mortality. In the model stratified by score ≤13, previous Rankin ≥3, and presence of atrial fibrillation were predictors of mortality. Conclusion: The relationship between time of arrival and mortality up to 90 days was modified by the National Institute of Health Stroke Scale. Prior Rankin ≥3, atrial fibrillation, time to arrival ≤4.5h, and age ≥60 years contributed to higher mortality.
RESUMEN Objetivo: Analizar la asociación entre el tiempo de llegada a un hospital de referencia y la mortalidad de las personas con accidente cerebrovascular isquémico. Método: Fueron usadas estadísticas descriptivas e inferenciales. En el análisis multivariado se verificaron variables modificadoras y confusoras entre el tiempo de llegada y la mortalidad. Para la elección del modelo se utilizó el Criterio de Información de Akaike. Se adoptó la significación estadística del 5% y la corrección del riesgo mediante el Modelo de Poisson. Resultados: La mayoría de los participantes llegaron dentro de las 4,5 horas posteriores al inicio de los síntomas o wake up stroke al hospital de referencia y el 19,4% fallecieron. La puntuación de la escala National Institute of Health Stroke Scale fue un modificador. En el modelo multivariante estratificado por puntaje de escala ≥14, el tiempo de llegada >4,5 h se asoció con una menor mortalidad; y edad ≥60 años y con Fibrilación Auricular a mayor mortalidad. En el modelo estratificado por puntaje ≤13, Rankin previo ≥3 y tener fibrilación auricular fueron predictores de mortalidad. Conclusión: La relación entre tiempo de llegada y mortalidad hasta los 90 días fue modificada por puntaje de la escala National Institute of Health Stroke Scale. Rankin previo ≥3, fibrilación auricular, tiempo hasta la llegada ≤4,5 h y la edad ≥60 años contribuyeron a una mayor mortalidad.
RESUMO Objetivo: Analisar a associação entre tempo de chegada a hospital de referência e mortalidade de pessoas com Acidente Vascular Cerebral isquêmico. Método: Foram utilizadas estatísticas descritivas e inferenciais. Variáveis modificadoras e confundidoras entre tempo de chegada e mortalidade foram verificadas na análise multivariada. O Critério de Informação de Akaike foi utilizado para escolha do modelo. Adotou-se significância estatística de 5% e correção de risco pelo Modelo de Poisson. Resultados: A maioria dos participantes chegou em até 4,5 horas do início dos sintomas ou wake up stroke ao hospital de referência e 19,4% morreram. A pontuação da National Institute of Health Stroke Scale foi um modificador. No modelo multivariado estratificado por pontuação da escala ≥14, o tempo de chegada >4,5h estava associado a menor mortalidade; e idade ≥60 anos e ter Fibrilação Atrial, a maior mortalidade. No modelo estratificado por pontuação ≤13, Rankin prévio ≥3 e ter fibrilação atrial foram preditores de mortalidade. Conclusão: A relação entre tempo de chegada e mortalidade até 90 dias foi modificada pela pontuação da National Institute of Health Stroke Scale. Rankin prévio ≥3, fibrilação atrial, tempo de chegada ≤4,5h e idade ≥60 anos contribuíram para maior mortalidade.
Subject(s)
Nursing , Stroke , Cohort Studies , MortalityABSTRACT
Mielopatia inflamatória ou mielite transversa é uma síndrome neurológica potencialmente incapacitante com uma variedade de etiologias. Episódios únicos ou recorrentes podem resultar em dependência de cadeira de rodas. O quadro clínico de fraqueza, alteração de sensibilidade e disfunção autonômica de início agudo ou subagudo é marca dessa síndrome. Esse cenário é comum às diferentes etiologias, que podem ser de natureza desmielinizante, por doença autoimune sistêmica, paraneoplásica ou infecciosa. A ressonância magnética de coluna é o exame de neuroimagem de escolha. Exames complementares como avaliação do líquido cefalorraquidiano, testes sorológicos e pesquisa de anticorpos dão suporte à investigação. A depender da etiologia, há tratamentos específicos a fim de reduzir incapacidade e chance de novos surtos, além de diferentes prognósticos. Este trabalho objetiva uma revisão de literatura sobre mielopatias inflamatórias e suas principais etiologias, a partir de dados obtidos na plataforma eletrônica PubMed. Para a discussão, foram revisadas as etiologias desmielinizantes (encefalomielite disseminada aguda, esclerose múltipla, doença do espectro, neuromielite óptica e neurite óptica, encefalite e mielite associadas ao MOG-IgG); doenças autoimunes (lúpus eritematoso sistêmico e síndrome de Sjögren); síndromes paraneoplásicas e mielopatias infecciosas (neuroesquistossomose, mielite por HIV e por HTLV-1 e neurossífilis). Concluiu-se com este estudo que a mielopatia inflamatória é uma condição de gravidade variável que produz potencial incapacidade, causada por diferentes etiologias, porém com quadro clínico comum entre elas. Por isso, é importante conhecer cada uma dessas causas, a fim de promover o melhor e mais precoce tratamento e reduzir sequelas.
Inflammatory myelopathy or transverse myelitis is a potentially disabling neurological syndrome with various etiologies. Single or recurrent episodes can result in wheelchair dependence. A clinical picture of weakness, altered sensitivity, and autonomic dysfunction with acute or subacute onset is characteristic of this syndrome. This scenario is common to different etiologies, which can be of a demyelinating nature, due to systemic, paraneoplastic, or infectious autoimmune disease. Spine MRI is the neuroimaging test of choice. Complementary tests such as cerebrospinal fluid evaluation, serological tests and antibody research support the investigation. Depending on the etiology, there are specific treatments to reduce disability and the chance of new episodes, and different prognoses. This study is a literature review on inflammatory myelopathies and their main etiologies, based on data obtained from the PubMed database. Demyelinating etiologies (acute disseminated encephalomyelitis, multiple sclerosis, neuromyelitis optic spectrum disease and optic neuritis, MOG-IgG-associated encephalitis and myelitis), autoimmune diseases (systemic lupus erythematosus and Sjögren's syndrome), paraneoplastic syndromes and infectious myelopathies (neuroschistosomiasis, HIV and HTLV-1 myelitis, and neurosyphilis) were reviewed for discussion. In conclusion, inflammatory myelopathy is a condition of variable severity that produces potential disability, caused by different etiologies, but with a common clinical picture between them. Thus, knowledge on each of these causes is important to promote the best and earliest treatment and reduce sequelae.
La mielopatía inflamatoria o mielitis transversa es un síndrome neurológico potencialmente incapacitante con una variedad de etiologías. Los episodios únicos o recurrentes pueden tener como consecuencia dependencia de silla de ruedas. El cuadro clínico de debilidad, sensibilidad alterada y disfunción autonómica de inicio agudo o subagudo es distintivo de este síndrome. Esto es común a diferentes etiologías, que pueden ser de naturaleza desmielinizante, debido a enfermedades autoinmunes sistémicas, paraneoplásicas o infecciosas. La resonancia magnética de columna es la prueba de neuroimagen de elección. Las pruebas complementarias, como la evaluación del líquido cefalorraquídeo, las pruebas serológicas y la investigación de anticuerpos respaldan la investigación. Dependiendo de la etiología, existen tratamientos específicos para reducir la discapacidad y la posibilidad de nuevos brotes, además de diferentes pronósticos. Este trabajo tiene como objetivo revisar la literatura sobre mielopatías inflamatorias y sus principales etiologías desde los datos obtenidos de la base de datos electrónica PubMed. Se revisaron las etiologías desmielinizantes (encefalomielitis aguda diseminada, esclerosis múltiple, enfermedad del espectro, neuromielitis óptico y neuritis óptica, encefalitis y mielitis asociadas a MOG-IgG), las enfermedades autoinmunes (lupus eritematoso sistémico y síndrome de Sjögren), los síndromes paraneoplásicos y mielopatías infecciosas (neurosquistosomiasis, mielitis por VIH y HTLV-1 y neurosífilis). Se concluyó que la mielopatía inflamatoria es una condición de severidad variable, que produce potencial discapacidad causada por diferentes etiologías, pero tiene un cuadro clínico común entre ellas. Por ello, es importante conocer cada una de las causas para promover el mejor y más precoz tratamiento, además de reducir las secuelas.
Subject(s)
HumansABSTRACT
BACKGROUND: Stroke is one of the most common causes of death and incapacity in the world. The benefits of reperfusion therapies and hospitalization in neurologic intensive care units (ICUs) are undeniable. However, these treatments are not widely available in a continental-sized country like Brazil. OBJECTIVE: To describe the treatment for ischemic stroke and the functional outcome 90 days after the hospitalization of patients in the Brazilian countryside. METHODS: Observational, prospective case series study design. The data collected refer to randomly selected patients hospitalized in 3 hospitals in the south region of the state of Bahia between December 2018 and December 2019. RESULTS: The population consisted of 61 consecutive patients. They were elderly (median age: 62 years old); with a predominance of hypertension (82%); and were light to moderate stroke cases (National Institute of Health Stroke Scale [NIHSS] median: 7). A total of 37.7% of the cases arrived at the hospital in a < 4.5-hour window but received no reperfusion therapy. Of these, 94.3% were discharged from the hospital with a prescription for antiplatelets or anticoagulant. A total of 64.1% of the patients received a statin prescription. At the end of the follow-up period, the general mortality was 21%. Almost half of the population (47.9%) evolved to an unfavored outcome (modified Rankin scale [mRs]: 3 to 6). CONCLUSION: Our population presented sociodemographic and comorbidities characteristics similar to those of other national samples. No reperfusion therapy was used and the treatment was basically secondary and prophylaxis-oriented, and almost half of the population evolved with incapacities and a high mortality rate, despite the initial low clinical gravity.
ANTECEDENTES: Acidente vascular cerebral (AVC) é uma das principais causas de morte e incapacidade no mundo. Os benefícios das terapias de reperfusão e hospitalização em unidade intensiva neurológica são inegáveis. Porém, estes tratamentos não estão largamente disponíveis em um país de dimensões continentais como o Brasil. OBJETIVOS: Descrever o tratamento do AVC isquêmico agudo e a funcionalidade, 90 dias após o evento, de pacientes hospitalizados no interior do Brasil. MéTODOS: Estudo observacional, prospectivo, tipo série de casos. Os dados foram coletados de pacientes consecutivos, aleatoriamente selecionados, internados em 3 hospitais da região Sul da Bahia entre dezembro de 2018 e dezembro de 2019. RESULTADOS: A população amostral consistiu de 61 pacientes. Houve predomínio de idosos (mediana de idade: 62 anos), hipertensos (82%), com AVC leve a moderado (mediana do National Institute ok Health Stroke Scale [NIHSS, na sigla em inglês]: 7), dos quais 37,7% chegaram ao hospital com < 4,5 horas de sintomas, mas não receberam terapias de reperfusão. Um total de 94,3% dos pacientes recebeu alta com prescrição de antiagregante plaquetário ou anticoagulante e 64,1% receberam prescrição de estatina. Ao final do período de seguimento, a mortalidade geral foi de 21% e quase metade da população amostral (47,9%) evoluiu com desfecho desfavorável (escala de Rankin modificada: 3 a 6). CONCLUSãO: A população amostral apresentou características sociodemográficas e comorbidades semelhantes às de outros recortes nacionais. Terapias de reperfusão não foram realizadas e o tratamento foi basicamente orientado para profilaxia secundária. Quase metade da população evoluiu com incapacidade ou morte, apesar da baixa gravidade clínica à admissão.
Subject(s)
Brain Ischemia , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Ischemic Stroke , Stroke , Aged , Anticoagulants/therapeutic use , Brain Ischemia/drug therapy , Brazil/epidemiology , Hospitals , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Middle Aged , Stroke/etiology , Treatment OutcomeABSTRACT
Abstract Background Stroke is one of the most common causes of death and incapacity in the world. The benefits of reperfusion therapies and hospitalization in neurologic intensive care units (ICUs) are undeniable. However, these treatments are not widely available in a continental-sized country like Brazil. Objective To describe the treatment for ischemic stroke and the functional outcome 90 days after the hospitalization of patients in the Brazilian countryside. Methods Observational, prospective case series study design. The data collected refer to randomly selected patients hospitalized in 3 hospitals in the south region of the state of Bahia between December 2018 and December 2019. Results The population consisted of 61 consecutive patients. They were elderly (median age: 62 years old); with a predominance of hypertension (82%); and were light to moderate stroke cases (National Institute of Health Stroke Scale [NIHSS] median: 7). A total of 37.7% of the cases arrived at the hospital in a < 4.5-hour window but received no reperfusion therapy. Of these, 94.3% were discharged from the hospital with a prescription for antiplatelets or anticoagulant. A total of 64.1% of the patients received a statin prescription. At the end of the follow-up period, the general mortality was 21%. Almost half of the population (47.9%) evolved to an unfavored outcome (modified Rankin scale [mRs]: 3 to 6). Conclusion Our population presented sociodemographic and comorbidities characteristics similar to those of other national samples. No reperfusion therapy was used and the treatment was basically secondary and prophylaxis-oriented, and almost half of the population evolved with incapacities and a high mortality rate, despite the initial low clinical gravity.
Resumo Antecedentes Acidente vascular cerebral (AVC) é uma das principais causas de morte e incapacidade no mundo. Os benefícios das terapias de reperfusão e hospitalização em unidade intensiva neurológica são inegáveis. Porém, estes tratamentos não estão largamente disponíveis em um país de dimensões continentais como o Brasil. Objetivos Descrever o tratamento do AVC isquêmico agudo e a funcionalidade, 90 dias após o evento, de pacientes hospitalizados no interior do Brasil. Métodos Estudo observacional, prospectivo, tipo série de casos. Os dados foram coletados de pacientes consecutivos, aleatoriamente selecionados, internados em 3 hospitais da região Sul da Bahia entre dezembro de 2018 e dezembro de 2019. Resultados A população amostral consistiu de 61 pacientes. Houve predomínio de idosos (mediana de idade: 62 anos), hipertensos (82%), com AVC leve a moderado (mediana do National Institute ok Health Stroke Scale [NIHSS, na sigla em inglês]: 7), dos quais 37,7% chegaram ao hospital com < 4,5 horas de sintomas, mas não receberam terapias de reperfusão. Um total de 94,3% dos pacientes recebeu alta com prescrição de antiagregante plaquetário ou anticoagulante e 64,1% receberam prescrição de estatina. Ao final do período de seguimento, a mortalidade geral foi de 21% e quase metade da população amostral (47,9%) evoluiu com desfecho desfavorável (escala de Rankin modificada: 3 a 6). Conclusão A população amostral apresentou características sociodemográficas e comorbidades semelhantes às de outros recortes nacionais. Terapias de reperfusão não foram realizadas e o tratamento foi basicamente orientado para profilaxia secundária. Quase metade da população evoluiu com incapacidade ou morte, apesar da baixa gravidade clínica à admissão.
ABSTRACT
ABSTRACT Objectives: to describe clinical characteristics and mortality of people with ischemic cerebrovascular accidents (strokes); to compare disability before the event and 90 days after. Methods: longitudinal study with 308 people hospitalized in Salvador-BA. Data collection took place from 03/2019 to 01/2020. Descriptive and inferential statistics were used. Results: mean age was 64.8 years, and National Institute of Health Stroke Scale score was 10.7. The median length of stay in the hospital was 11 days. Afro-descendants predominated (84%), elementary educational level (68.4%), income up to three minimum wages (89.1%), arrival within 4.5 hours of symptoms (57.9%) and admission to a specialized unit (71.8%). Prevalence of thrombolysis: 26%. The asymptomatic before the event category predominated (85.3%) as did the moderate/severe disability (41.5%) after 90 days. 19.7% of the sample evolved to death. Conclusions: the high mortality and disability generated by the event have implications for health management and care.
RESUMEN Objetivos: describir características clínicas y la mortalidad de personas con accidente cerebrovascular isquémico; comparar la discapacidad antes del evento y 90 días después. Métodos: estudio longitudinal, con 308 personas hospitalizadas en Salvador-BA. Recolecta de datos ocurrió de 03/2019 a 01/2020. Empleado estadística descriptiva e inferencial. Resultados: la mediana de edad fue de 64,8 años, y la puntuación de la National Institute of Health Stroke Scale fue 10,7. La mediana del tiempo de internación fue de 11 días. Predominaron negros (84%), hasta la educación primaria (68,4%), renta hasta tres salarios mínimos (89,1%), llegada hasta 4,5 horas del inicio de los síntomas (57,9%) e internación en unidad especializada (71,8%). Realizaron trombolisis: 26%. Predominó la categoría asintomática (85,3%) antes del evento y discapacidad moderada/severa (41,5%) tras 90 días. Óbito alcanzó 19,7% de la muestra. Conclusiones: la alta mortalidad y discapacidad generadas por el evento hay implicaciones a la gestión y cuidado en salud.
RESUMO Objetivos: descrever características clínicas e a mortalidade de pessoas com acidente vascular cerebral isquêmico; comparar a incapacidade antes do evento e 90 dias depois. Métodos: estudolongitudinal, com 308 pessoas hospitalizadas em Salvador-BA. A coleta de dados ocorreu de 03/2019 a 01/2020. Empregou-se estatística descritiva e inferencial. Resultados: a média de idade foi de 64,8 anos ( dp=14,1) e a pontuação da National Institute of Health Stroke Scale foi 10,7 (dp=7,2). Amediana do tempo de internação foi de 11 dias. Predominaram negros (84,0%), escolaridade até o fundamental (68,4%), renda até três salários mínimos (89,1%), chegada até 4,5 horas do início dos sintomas (57,9%) e internação em unidade especializada (71,8%). Realizaram trombólise: 26,0%. Predominou a categoria assintomática (85,3%) antes do evento e incapacidade moderada/severa (41,5%) após 90 dias (p= 0.117). Óbito atingiu 19,7% da amostra. Conclusões: a alta mortalidade e incapacidade geradas pelo evento têm implicações para a gestão e cuidado em saúde.
ABSTRACT
OBJECTIVES: to describe clinical characteristics and mortality of people with ischemic cerebrovascular accidents (strokes); to compare disability before the event and 90 days after. METHODS: longitudinal study with 308 people hospitalized in Salvador-BA. Data collection took place from 03/2019 to 01/2020. Descriptive and inferential statistics were used. RESULTS: mean age was 64.8 years, and National Institute of Health Stroke Scale score was 10.7. The median length of stay in the hospital was 11 days. Afro-descendants predominated (84%), elementary educational level (68.4%), income up to three minimum wages (89.1%), arrival within 4.5 hours of symptoms (57.9%) and admission to a specialized unit (71.8%). Prevalence of thrombolysis: 26%. The asymptomatic before the event category predominated (85.3%) as did the moderate/severe disability (41.5%) after 90 days. 19.7% of the sample evolved to death. Conclusions: the high mortality and disability generated by the event have implications for health management and care.
Subject(s)
Disabled Persons , Stroke , Hospitalization , Humans , Longitudinal Studies , Middle Aged , Stroke/complications , Treatment OutcomeABSTRACT
The second part of these Guidelines covers the topics of antiplatelet, anticoagulant, and statin therapy in acute ischemic stroke, reperfusion therapy, and classification of Stroke Centers. Information on the classes and levels of evidence used in this guideline is provided in Part I. A translated version of the Guidelines is available from the Brazilian Stroke Society website (www.sbdcv.com.br).
Subject(s)
Anticoagulants/therapeutic use , Brain Ischemia/drug therapy , Fibrinolytic Agents/therapeutic use , Stroke/drug therapy , Thrombolytic Therapy/standards , Aspirin/therapeutic use , Heparin/therapeutic use , Humans , Platelet Aggregation Inhibitors/therapeutic use , ReperfusionABSTRACT
The second part of these Guidelines covers the topics of antiplatelet, anticoagulant, and statin therapy in acute ischemic stroke, reperfusion therapy, and classification of Stroke Centers. Information on the classes and levels of evidence used in this guideline is provided in Part I. A translated version of the Guidelines is available from the Brazilian Stroke Society website (www.sbdcv.com.br).
A segunda parte das Diretrizes aborda os tópicos de antiagregantes plaquetários, anticoagulantes e terapia de reperfusão para acidente vascular cerebral (AVC) isquêmico. Os critérios para nível de evidência e graus de recomendação estão contidos na primeira parte do documento. Uma versão traduzida destas Diretrizes encontra-se publicada no portal da Sociedade Brasileira de Doenças Cerebrovasculares (www.sbdcv.org.br).